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Coq9 is required for the stability of a mitochondrial multi-subunit complex, termed
the CoQ-synthome, and the deamination step of Q intermediates that derive from
para-aminobenzoic acid (pABA) in yeast. In human, mutations in the COQ9 gene
cause neonatal-onset primary Q10 deficiency. In this study, we determined whether
expression of human COQ9 could complement yeast coq9 point or null mutants. We
found that expression of human COQ9 rescues the growth of the temperature-sensitive
yeast mutant, coq9-ts19, on a non-fermentable carbon source and increases the
content of Q6, by enhancing Q biosynthesis from 4-hydroxybenzoic acid (4HB). To
study the mechanism for the rescue by human COQ9, we determined the steady-state
levels of yeast Coq polypeptides in the mitochondria of the temperature-sensitive
yeast coq9 mutant expressing human COQ9. We show that the expression of
human COQ9 significantly increased steady-state levels of yeast Coq4, Coq6, Coq7,
and Coq9 at permissive temperature. Human COQ9 polypeptide levels persisted at
non-permissive temperature. A small amount of the human COQ9 co-purified with
tagged Coq6, Coq6-CNAP, indicating that human COQ9 interacts with the yeast
Q-biosynthetic complex. These findings suggest that human COQ9 rescues the yeast
coq9 temperature-sensitive mutant by stabilizing the CoQ-synthome and increasing
Q biosynthesis from 4HB. This finding provides a powerful approach to studying the
function of human COQ9 using yeast as a model.
Keywords: human homolog, temperature-sensitive mutant, coenzyme Q, immunoprecipitation, Saccharomyces
cerevisiae, mitochondrial metabolism
Abbreviations: 4-AP, 3-hexaprenyl-4-aminophenol; DDMQ6, demethyl-demethoxy Q6; DMQ6, demethoxy-Q6; HAB,
3-hexaprenyl-4-aminobenzoic acid; 4HB, 4-hydroxybenzoic acid; HHB, 3-hexaprenyl-4-hydroxybenzoic acid; 4-HP,
3-hexaprenyl-4-hydroxyphenol; IDDMQ6, imino-demethyl-demethoxy Q6; IDMQ6, imino-demethoxy-Q6 ; mcCOQ8, multi-
copy COQ8; pABA, para-aminobenzoic acid; RP-HPLC-MS/MS; reverse phase-HPLC-MS/MS; Q, Coenzyme Q.
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INTRODUCTION
Coenzyme Q (Q) is a lipid that functions as an electron and
proton carrier in the mitochondrial respiratory chain and as a
lipid-soluble antioxidant (Turunen et al., 2004). Q is composed
of a redox-active benzoquinone ring and a polyisoprenoid
side chain, which contains six isoprene units in Saccharomyces
cerevisiae (Q6) and ten isoprene units in humans (Q10) (Crane
and Barr, 1985). Both yeast and human cells are able to
use 4-hydroxybenzoic acid (4HB), resveratrol, and coumarate
to synthesize Q (Xie et al., 2015). However, while para-
aminobenzoic acid (pABA) is a ring precursor for Q in yeast
(Marbois et al., 2010), mammalian cells cannot synthesize Q from
pABA (Xie et al., 2015). The biosynthetic pathway of Q is highly
conserved among species. Genes involved in Q biosynthesis in
yeast include COQ1-10, YAH1, and ARH1, all of which have
human homologs (Desbats et al., 2015). A new gene involved
in yeast Q biosynthesis was recently identified as COQ11 (Allan
et al., 2015), and whether the human homolog is also involved in
Q biosynthesis requires further investigation. Most of the human
homologs of yeast COQ genes rescue the corresponding yeast
coq mutants. For example, co-expression of PDSS1 and PDSS2
rescue the yeast coq1mutant (Kawamukai, 2015) and expression
of COQ8A (formerly identified as ADCK3) rescues the yeast coq8
mutant (Xie et al., 2011). Similarly expression of human COQ2,
COQ3, COQ4, COQ6, COQ7, COQ10A, (Wang and Hekimi,
2013; Desbats et al., 2015), or COQ5 (Nguyen et al., 2014) each
rescue the corresponding yeast coqmutant.
Yeast Coq9 is required for the function of Coq6 and Coq7
polypeptides in Q6 biosynthesis, and is essential for the stability
of the CoQ synthome (Hsieh et al., 2007; He et al., 2014). Yeast
Coq9 function is not fully understood, but it is required for
the deamination of nitrogen-containing Q intermediates derived
from pABA. For example, imino-demethoxy-Q6 (IDMQ6) and
3-hexaprenyl-4-aminophenol (4-AP) accumulate in the yeast
coq9 null mutant fed pABA in the setting of COQ8 over-
expression (Xie et al., 2012). The over-expression of yeast COQ8
in several of the coq null mutants has been shown to stabilize the
Q-biosynthetic complex and to facilitate formation of late-stage
Q-intermediates (Xie et al., 2012). A distinct nitrogen-containing
Q-intermediate, imino-demethyl-demethoxy Q6 (IDDMQ6) also
accumulates in the pABA-fed yeast double coq9 null + coq5-
5 point mutant (He et al., 2015). In contrast, the coq5-5 single
mutant is able to produce demethyl-demethoxy Q6 (DDMQ6)
when fed pABA (Nguyen et al., 2014; He et al., 2015). These
results suggest that yeast Coq9 functions either directly or
indirectly to remove amino substituents from Q-intermediates
that derive from pABA.
In previous work we generated a coq9 temperature sensitive
mutant plasmid using site-directed mutagenesis of the wild-type
yeast COQ9, coq9-ts19 (TS19). TS19 contains the following
point mutations: Adenine-12:Guanine (a-12g), Adenine-
93:Guanine (a-93g), Glu55:Gly (a164g; E55G), Arg107:Gly
(a319g; R107G), and Gln256:Leu (a767t; Q256L). This mutant
grew as well as wild type at the permissive temperature of
25◦C and grew poorly at the non-permissive temperature of
37◦C. We found that at the non-permissive temperature, the
levels of Coq9-ts19 polypeptide increased, but other yeast
Coq polypeptides, Coq4, Coq5, Coq6, and Coq7 decreased
and nitrogen-containing intermediates derived from pABA
accumulated (He et al., 2015). This phenomenon is not
understood; it may be that while the function of the Coq9-ts19
polypeptide is impaired with respect to wild-type Coq9, the
mutations confer some form of thermal stability to the protein
such that it is resistant to degradation at higher temperatures.
Alternatively, the coq9-ts19 mutant contains two mutations
upstream of the start codon, which may lead to more robust
expression of the protein at the non-permissive temperature.
In either case, the Coq9-ts19 polypeptide at the restrictive
temperature is not fully functional, and leads to a drastic
decrease in Q content (He et al., 2015). This in turn would
impact the stability of the CoQ synthome and steady state levels
of the Coq4, Coq5, and Coq7 polypeptides.
Taken together, these results indicate that yeast Coq9 is
required to remove the nitrogen group of Q intermediates
derived from pABA. Interestingly, human cells cannot synthesize
Q from pABA (Xie et al., 2015). Thus, human COQ9 may lack
the ability to aid in the deamination step(s) that are normally
required in yeast Q biosynthesis from pABA.
It is clear that human COQ9 is required for Q10 biosynthesis;
a mutation in the COQ9 gene was identified in a patient with
neonatal-onset primary Q10 deficiency (Duncan et al., 2009).
The patient harbored a homozygous nonsense mutation in
COQ9, resulting in a truncated COQ9 polypeptide (Arg244Ter),
presented with neonatal lactic acidosis, and later developed
multisystem disease including intractable seizures, global
developmental delay, hypertrophic cardiomyopathy, and renal
tubular dysfunction. Cultured skin fibroblasts from the patient
were examined and found to contain low levels of Q10 relative to
control subjects and a compound slightly more polar than Q10,
suggestive of a Q10-intermediate (Duncan et al., 2009). Recently
another patient who manifested fatal neonatal lactic acidosis and
encephalopathy was diagnosed with a COQ9 deficiency due to
a splice site mutation that caused skipping of exons four and
five (Danhauser et al., 2016). The content of Q10 in cultured
fibroblasts derived from the patient was only 8–16% of normal
levels, and demethoxy-Q10, a biosynthetic Q-intermediate,
was readily detected (Danhauser et al., 2016). A third patient
with a homozygous missense mutation in COQ9 resulted in a
missense COQ9 polypeptide (His62Arg), and was diagnosed
with a primary deficiency in Q10 (Alfadhel et al., 2016).
Garcia-Corzo and co-workers generated a Coq9 knockin
mouse model by introducing the Coq9-R239X mutation that
recapitulates the Arg244Ter human COQ9 mutation (Garcia-
Corzo et al., 2013). The Coq9R239X/R239X homozygous knockin
mice showed histologic and behavioral signs that mirrored
mitochondrial encephalomyopathy associated with primary Q
deficiency in human patients. A widespread Q deficiency was
noted in these mice along with a dramatic reduction in the
steady state level of the COQ7 polypeptide and accumulation of
demethoxy-Q9 (DMQ9) (Garcia-Corzo et al., 2013). A second
Coq9mouse model (Coq9Q95X) also demonstrated that COQ9 is
required for Q biosynthesis (Luna-Sanchez et al., 2015). However,
the Q deficiency in the Coq9Q95X/Q95X mice is less severe than
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in the Coq9R239X/R239X mice, probably due to differences in
nonsense-mediated decay efficiency and in the stability of the
CoQ synthome (Luna-Sanchez et al., 2015).
A recent study determined the structure of human COQ9
(Lohman et al., 2014). Human COQ9 functions as a dimer and
has a hydrophobic interface that binds lipids and a surface patch
that binds human COQ7 (Lohman et al., 2014). Taken together
these results suggest that the COQ9 polypeptide is required for
COQ7 function in yeast, mouse, and human Q biosynthesis.
Yeast has been a great model for the study of Q biosynthesis;
it can be a powerful system to study human COQ proteins with
unknown functions. In most cases, expression of human COQ
homologs, rescue the corresponding yeast coq mutants (Wang
and Hekimi, 2013; Hayashi et al., 2014). For example, human
COQ6 expressed from a plasmid with yeast mitochondrial leader
sequence rescued the yeast coq6 null mutant for growth on a
non-fermentable carbon source (Heeringa et al., 2011); in the
yeast coq5 null mutant over-expressing COQ8, expression of
human COQ5 with its first 55 amino acids replaced by the first
54 amino acids of yeast Coq5 restored Q6 content and growth
on a non-fermentable carbon source (Nguyen et al., 2014).
However, expression of human COQ9 in yeast fails to restore Q
biosynthesis in yeast coq9 mutants (Duncan et al., 2009; Hayashi
et al., 2014). In this study, we tested whether human COQ9 could
rescue Q biosynthesis in distinct yeast coq9 mutants. The results
presented indicate that under certain conditions human COQ9
functions to restore yeast Q biosynthesis, but that the potential of
yeast Coq9 to remove amino/imino groups fromQ-intermediates
is a functional role that is not shared with human COQ9.
MATERIALS AND METHODS
Yeast Strains and Growth Media
Saccharomyces cerevisiae strains used in this study are listed in
Table 1. Growth media used in this study included: YPD (2%
glucose, 1% yeast extract, 2% peptone), YPGal (1% yeast extract,
2% peptone, 2% galactose, 0.1% dextrose), and YPG (3% glycerol,
1% yeast extract, 2% peptone), and were prepared as described
(Burke et al, 2000). Synthetic Dextrose (SD)/Minimal medium
consisted of 0.18% yeast nitrogen base without amino acids, 2%
dextrose, 0.14% NaH2PO4, 0.5% (NH4)2SO4, and amino acids
added to final concentrations as described (Barkovich et al.,
1997). Selective SD/Minimal medium lacking uracil (SD–Ura)
and selective SD/Minimal medium lacking uracil and leucine
(SD–Ura–Leu) were similarly prepared. Agar plate media were
prepared as described above and included 2% Bacto agar (Fisher).
Construction of Plasmids
COQ8 was over-expressed in yeast with the p4HN4 plasmid
(mcCOQ8). The COQ8 gene was cloned into pRS426, a multi-
copy yeast shuttle vector, resulting in mcCOQ8 (Hsieh et al.,
2004). To construct plasmids expressing human COQ9, we
cloned human COQ9 into pQM (Hsu et al., 1996) and pRCM
(Allan et al., 2013). These are respectively low- and multi-copy
vectors that express ORFs fused to the yeast Coq3 amino
terminal mitochondrial leader sequence (amino acids 1–34)
under control of the yeast CYC1 promoter. Human COQ9 was
amplified from pBGcoq9, which contains the human COQ9
ORF in YEpJB1-21-10 and is expressed from a constitutive
PGK promoter (Duncan et al., 2009). The human COQ9
ORF was amplified with Taq polymerase and primers Hcoq9F
(5′-ATCGATATGGCGGCGG CGGCGGTAT-3′ with a ClaI
restriction site at the 5′ end) and HcoqR (5′-GGTACCTC
ACCGACGCTGGTTTAGACCTGTCAAGTTCTTGAGC-3′
with a KpnI restriction site at the 5′ end). PCR products were
inserted into the TOPO vector resulting in a plasmid named
HCOQ9TOPO. HCOQ9TOPO was digested with the restriction
enzymes ClaI and KpnI (New England BioLabs) and inserted
in pQM or pRCM prepared with ClaI and KpnI, resulting
in the plasmids scHCOQ9 and mcHCOQ9, respectively. The
nucleotide sequence of the human COQ9 ORF in scHCOQ9 and
mcHCOQ9 was confirmed by sequencing (UCLA sequencing
core, Los Angeles).
Disruption of COQ9 in W3031B Yeast Strain
A PCR product containing the KanMX4 gene was amplified
with the genomic DNA isolated from BY47411coq9 (used as
template) with primers that annealed 100 bp upstream and
downstream of the COQ9 ORF. The sequences of the primers
utilized were: 5′-TTTGGGCCTACATAAGGTACTTC-3′ and 5′-
CGCACAGACCAATAAATCTGCC-3′. The PCR product was
then transformed into the yeastW3031B to createW3031coq9K.
Transformants that grew on YPD+ 200 µg/ml G418 (Geneticin)
were selected. Proteins were extracted from these transformants
TABLE 1 | Genotype and Source of Yeast Strains.
Strain Genotype Source
W3031B MAT α ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 R. Rothsteina
W3031COQ4 MAT α ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 coq4::TRP1 Hsu et al., 2000
W3031COQ6 MAT α ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 coq6::LEU2 Gin et al., 2003
W3031COQ7 MAT α ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 coq7::LEU2 Marbois and Clarke, 1996
BY4741∆COQ9 MAT α coq9∆::kanMX4 his3∆1 leu2∆0 lys2∆0 ura3∆0 Winzeler et al., 1999b
W3031coq9K MAT α ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 coq9::KanMX4 This study
Coq6-CNAP Mat α ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 COQ6::COQ6-CNAP-HIS3 Allan et al., 2015
aDr. Rodney Rothstein, Department of Human Genetics, Columbia University.
bEuropean S. cerevisiae Archive for Functional Analysis (EUROSCARF), available on-line.
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as described (Yaffe and Schatz, 1984) and separated by SDS-
PAGE with a 10% polyacrylamide gel. Proteins were transferred
to an Immobilon-P transfer membrane (Millipore) and analyzed
by immunoblotting as described (He et al., 2014). The primary
antibody against Coq9 was used at a 1:1000 dilution and the
secondary antibody, goat anti-rabbit IgG H&L chain specific
peroxidase conjugate (Calbiochem), at a 1:10,000 dilution. The
absence of Coq9 polypeptide confirmed that COQ9 was replaced
with KanMX4.
Lipid Extraction and Detection of
Q6-Intermediates by HPLC and Tandem
Mass Spectrometry
The de novo synthesis of Q6 and Q6-intermediates was tracked
in yeast cells labeled with 13C6-pABA or
13C6-4HB followed
by lipid analysis. Labeling media were prepared with 10 µg/ml
13C6-pABA or
13C6-4HB dissolved in ethanol (0.2% final
concentration). After 12.5 h of labeling cells were collected (a
total of 50 A600 nm) as pellets by centrifugation. Q4 was added
(164 pmol) to each cell pellet to serve as an internal standard.
Lipid extracts were analyzed by RP-HPLC-MS/MS (Xie et al.,
2012). For liquid chromatography, a phenyl-hexyl column (Luna
5u, 100 × 4.60 mm, 5-µm, Phenomenex) was used. The mobile
phase consisted of Solvent A (methanol/isopropanol, 95:5, with
2.5 mM ammonium formate) and Solvent B (isopropanol, 2.5
mM ammonium formate). Solvent B was increased linearly from
0 to 5% with the flow rate increased from 600 to 800 µl/min from
0 to 6 min. The flow rate and mobile phase were changed back to
600 µl/min and 100% Solvent A respectively at 7 min. Multiple
reaction monitoring mode (MRM) analysis was performed with
the 4000 QTRAP linear MS/MS spectrometer from Applied
Biosystems (Foster City, CA). Data were processed with Analyst
version 1.4.2 software (Applied Biosystems).
To quantify Q6 content, the peak areas of
12C-Q6 (sum
of oxidized and reduced) and 13C6-Q6 (sum of oxidized
and reduced) were normalized by the peak areas of Q4
(sum of oxidized and reduced); the pmol amounts were
then determined from the Q6 standard curve. The pmol of
12C-Q6 and
13C6-Q6 were further normalized by the yeast
pellet wet weights. A chemical standard for DMQ6 is not
available. To quantify this intermediate, the peak areas (sum
of oxidized and reduced DMQ6) were normalized by the
recovery of Q4 (sum of oxidized and reduced peaks). Finally,
calculated values were further normalized by the yeast pellet wet
weights.
Mitochondria Isolation and Immunoblot
Analyses with Yeast coq9
Temperature-Sensitive Mutants Expressing
the Human COQ9 Homolog
Yeast cultures were grown to 3–4 A600 nm/ml in YPGal medium
at different temperatures (W3031B, W3031coq9:TS19, and
W3031coq9:TS19+mcHCOQ9 were grown at 25 and 37◦C
for 18.5 h; BY47411COQ9, W3031COQ7, W3031COQ4,
W3031COQ6 were grown at 30◦C overnight). Crude
mitochondria were isolated from 1 L of culture as described
(Padilla-López et al., 2009). Mitochondria were further
purified with an OptiPrep discontinuous iodixanol gradient
as described (He et al., 2014). The bicinchoninic acid assay
was used to measure the total protein concentration in purified
mitochondria (ThermoFisher Scientific). Purified mitochondria
were solubilized with digitonin as described (He et al., 2014), and
15 µg of mitochondria were separated by SDS-PAGE with 10%
polyacrylamide gels. Proteins were transferred to Immobilon-P
transfer membranes (Millipore) and immunoblot analyses were
performed as described (He et al., 2014). The source and use of
primary antibodies are described in Table 2. Goat anti-rabbit IgG
H&L chain specific peroxidase conjugate (Calbiochem), 1:10,000
was used as the secondary antibody.
Co-Precipitation of Coq6-CNAP
Expressing the Human COQ9 Homolog
Purified mitochondrial proteins (13 mg; 2 mg/ml) were
solubilized with 4 mg/ml digitonin as described earlier.
The soluble digitonin extract was collected after 100,000 ×
g centrifugation (Optimax TLX). Co-precipitation was then
performed on the solubilized mitochondria with Ni-NTA resin
(Qiagen) as described in Allan et al. (2015). Briefly, Ni-NTA
resin (800 µl bed volume) was equilibrated with two volumes
of lysis buffer. Solubilized mitochondria and 8 ml of lysis buffer
were added to 800 µl of pre-equilibrated Ni-NTA resin (bed
volume) in a 15 ml Falcon tube and rotated for 1.5 h at 4◦C. The
resin-slurry was applied to a column and the flow-through was
collected. The resin was washed twice with Ni-NTA wash buffer
(W1 and W2) and eluted twice with Ni-NTA elution buffer (E1
and E2). Aliquots of each fraction were examined for presence
of Coq polypeptides: 0.17% of the FT, 0.25% of W1, 0.25% of
W2, 1% of E1, 0.5% of E2, and 1.25% of Ni-NTA resin were
analyzed by SDS-PAGE followed by immunoblot analysis with
antibodies against Coq9, human COQ9 (1:1,000), Coq6, 1:250
and Atp2, 1:4,000. Purified mitochondria (15 µg protein) from
CNAP6:mcHCOQ9 were included as a control.
RESULTS
Expression of a Human COQ9 Homolog
Rescues the Growth of the ∆coq9K:TS19
Mutant on Medium Containing a
Non-fermentable Carbon Source
Expression of human COQ9 has previously failed to rescue yeast
coq9 null mutant growth on non-fermentable carbon sources
(Duncan et al., 2009; Hayashi et al., 2014). It seemed likely that
TABLE 2 | Description and Source of Antibodies.
Antibody Working dilution Source
Atp2 1:4000 Carla M. Koehlera
Coq4 1:250 Belogrudov et al., 2001
Coq6 1:250 Gin et al., 2003
Coq7 1:1000 Tran et al., 2006
Coq9 1:1000 Hsieh et al., 2007
Human COQ9 1:1000 Proteintech Group, Inc.
aDr. Carla M. Koehler, Department of Chemistry and Biochemistry, UCLA.
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the destabilization of other Coq polypeptides in the yeast coq9
null mutant might account for the inability of human COQ9 to
rescue the mutant. To stabilize other Coq polypeptides in the
coq9 null mutant, we co-expressed multi-copy COQ8 (mcCOQ8)
with either single copy (scHCOQ9) or multi-copy human COQ9
(mcCOQ9) in a coq9 null yeast mutant (W30319K) and tested
its growth on YPG plate medium, containing glycerol as the
sole non-fermentable carbon source. However, expression of
mcCOQ8 alone did not enable humanCOQ9 to rescue the growth
of the coq9 null mutant (Figure 1).
Next, we turned to the ∆coq9K:TS19 mutant, which
retains detectable steady-state levels of the yeast Coq9-
TS19 polypeptide and other Coq polypeptides, is able to
grow on YPG at the permissive temperature (25◦C) (He
et al., 2015), but shows defective growth on YPG at the
non-permissive temperature (37◦C; Figure 1). Expression of
mcCOQ8, scHCOQ9, or mcHCOQ9 were each able to rescue the
growth of the1coq9:TS19 mutant on YPG at the non-permissive
temperature. While expression of yeast COQ9 yielded the most
robust rescue at the non-permissive temperature, expression
of mcCOQ8 and mchCOQ9 also rescued growth of the coq9
null mutant, with schCOQ9 providing noticeably less rescue
(Figure 1). At the permissive temperature it is not possible to
distinguish the effects of single-copy human COQ9 or multi-
copy COQ8. The yeast ∆coq9K:TS19 mutant still functions
at 25◦C, and its growth is similar to wild type. However,
there is a slight increase of growth of ∆coq9K:TS19 harboring
mcHCOQ9. Yeast cells were also plated on SD-Ura-Leu to
confirm that W30319K was successfully transformed with the
two plasmids. The empty vector pRS426, which is the parent
vector of mcCOQ8, was included as a control (EV). As expected,
∆coq9K:TS19 cannot be rescued by the empty vector (Figure 1).
Therefore, the rescue effects were specific and depended on the
expression of either human COQ9 or over-expression of yeast
COQ8.
In the Yeast ∆coq9K:TS19 Mutant,
Expression of Human COQ9 Increased the
De novo Synthesis of Q6 from 4HB and
Over-Expression of Coq8 Increased the De
novo Synthesis of Q6 from pABA
Yeast Coq9 is required to remove the nitrogen group from Q6
intermediates derived from pABA (He et al., 2015). To assess
whether this function is manifested by the expression of human
COQ9 in yeast, we determined the de novo synthesis of 13C6-Q6
from either 13C6-pABA or
13C6-4HB. The yeast ∆coq9K:TS19
mutant was transformed with the designated plasmids and levels
of Q6 and Q6 intermediates were determined at permissive
and non-permissive temperatures. The presence of mcCOQ8
significantly increased the amount of 13C6-Q6 synthesized from
13C6-pABA at the permissive temperature relative to the empty
vector control (Figure 2A). At the non-permissive temperature,
mcCOQ8 and both the scHCOQ9 and mcHCOQ9 plasmids
increased the amount of 13C6-Q6 synthesized from
13C6-pABA
(Figure 2A). In contrast, mcCOQ8 and the human COQ9
homolog increased the amount of 13C6-Q6 synthesized from
13C6-4HB at the permissive temperature, but only the human
COQ9 homolog increased the amount of 13C6-Q6 synthesized
from 13C6-4HB at the non-permissive temperature (Figure 2D).
There is a significant increase of 13C6-DMQ6 in ∆coq9K:TS19
with the expression of mcCOQ8 and both the scHCOQ9 and
mcHCOQ9 (Figures 2B,E). Interestingly, mcHCOQ9 has the
most dramatic effect on 13C6-DMQ6 levels when
13C6-4HB
FIGURE 1 | Expression of human COQ9 or over-expression of COQ8 rescues the growth of the temperature-sensitive coq9 mutant on a non-fermentable carbon
source. W30319K was transformed with TS19 and one of the following plasmids: empty vector pRS426 (EV), multi-copy yeast COQ8 (mcCOQ8), single-copy human
COQ9 (scHCOQ9), and multi-copy human COQ9 (mcHCOQ9). Yeast strains were cultured in SD-Leu-Ura media overnight at 25◦C. W3031B (WT), W30319K,
W30319K:COQ9, and W30319K:TS19 were used as controls and grown in YPG and SD-Leu respectively. Cell cultures were diluted to 0.2 A600 nm/ml and 2 µl of
1:5 serial dilutions were spotted onto SD-Ura-Leu or YPG plate media and incubated at either 25◦C or 37◦C for 3 days.
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FIGURE 2 | Expression of human COQ9 or over-expression of COQ8 increases the content of Q6 and DMQ6 in W30319K expressing the temperature-sensitive
plasmid TS19. W30319K was transformed with TS19 and one of the following plasmids: empty vector pRS426 (EV), multi-copy yeast COQ8 (mcCOQ8), single-copy
of human COQ9 (scHCOQ9), and multi-copy of human COQ9 (mcHCOQ9). One colony of each type of yeast transformant was seeded in selective media,
SD-Ura-Leu, and grown overnight. The cell culture was diluted to 0.1A600 nm/ml in 20 ml of fresh SD-Ura-Leu containing 10 µg/ml
13C6-pABA (A–C) or 10 µg/ml
(Continued)
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FIGURE 2 | Continued
13C6-4HB (D–F) dissolved in 2 µl ethanol/ml medium and grown at 25 or 37
◦C for 12.5 h. Final cell density was between 3 and 5 A600 nm/ml. Yeast cells
(corresponding to a total of 50 A600 nm) were collected as pellets, from which lipids were extracted and analyzed by RP-HPLC-MS/MS. Each bar represents a total
four measurements from two independent samples each with two injections. Black bars represent the amount of 12C-Q6, red bars represent
13C6-Q6 and
13C6-DMQ6 labeled by
13C6-pABA and blue bars represent
13C6-Q6 and
13C6-DMQ6 labeled by
13C6-4HB. The amounts of the
12C- and 13C6-compounds
represent the sum of reduced and oxidized forms. Both Q6 and
13C6-DMQ6 levels were higher in W30319K:TS19 harboring human COQ9 homolog or
over-expression of COQ8 as compared to W30319K:TS19 harboring empty vector as determined by the Student’s two-tailed t-test. The * symbols represent
samples at 25◦C compared to W30319K:TS19+EV at 25◦C; ** p < 0.01, ***p < 0.001. The + symbols represent samples at 37◦C compared to
W30319K:TS19+EV at 37◦C; +p < 0.05, ‡p < 0.01, +++p < 0.001. When there is no significant change, ns was used to designate “non-significant.”
was provided at non-permissive temperature (Figure 2E). These
findings suggest that expression of human COQ9 rescues
the ∆coq9K:TS19 mutant by increasing Q biosynthesis with
4HB as the precursor. The levels of 12C-Q6 were elevated
by mcCOQ8 and human COQ9 at both permissive and non-
permissive temperatures (Figures 2C,F), perhaps indicating that
mcCOQ8 and human COQ9may enhance the utilization of other
(unlabeled) ring precursors to increase Q content.
In the Yeast ∆coq9K:TS19 Mutant,
Expression of Human COQ9 Stabilizes
Yeast Coq Polypeptides at Permissive
Temperature
To investigate the mechanisms responsible for the rescue of
the ∆coq9K:TS19 mutant by human COQ9, we determined
whether human COQ9 stabilizes other Coq polypeptide levels.
Wild type (WT), ∆coq9K:TS19 (19K:TS19) and 19K:TS19+
mcHCOQ9 yeast were cultured in YPGal for 18.5 h at either 25
or 37◦C, and mitochondria were isolated. Steady-state levels of
Coq4, Coq6, Coq7, Coq9, and human COQ9 were analyzed by
immunoblotting (Figure 3). The levels of Atp2 were analyzed
as a loading control. At the non-permissive temperature, the
expression of Coq9-ts19 resulted in lower steady-state levels of
the other yeast Coq polypeptides and human COQ9. In contrast,
in wild-type yeast, Coq4, Coq6, Coq7, and Coq9 levels were
increased at 37◦C (Figure 3). In the∆coq9K:TS19mutant, Coq9-
ts19 levels were increased at 37◦C (Figure 3A), while steady-
state levels of the Coq4, Coq6, and Coq7 polypeptides were
decreased at 37◦C (Figure 3). The changes of Coq polypeptides
in either wild type or the temperature-sensitive mutant at
different temperatures did not result from changes in the
corresponding COQ RNA levels (He et al., 2015). When human
COQ9 was expressed in ∆9K:TS19 (19K:TS19+ mcHCOQ9),
the steady state levels of Coq4, Coq6, Coq7, and Coq9 were
significantly increased at the permissive temperature (Figure 3).
The results suggest that at permissive temperature the expression
of human COQ9 stabilizes certain yeast Coq polypeptides.
Two distinct polypeptides were detected in the mitochondria
of ∆9K:TS19+mcHCOQ9 with the antibody against human
COQ9. Based on the mass of the polypeptides, it seems likely
that the larger polypeptide corresponds to unprocessed human
COQ9 with the mitochondrial leader (39 kDa), and the smaller
polypeptide represents processed human COQ9 (30.5 kDa).
At non-permissive temperature, steady-state levels of human
COQ9 were also decreased (Figure 3A). The observed decrease is
specific to human COQ9 and Coq proteins of the CoQ synthome
because the steady state levels of Atp2, the beta subunit of the F1
sector of the mitochondrial F1F0 ATP synthase, did not change at
higher temperature. These results suggested that human COQ9
may be associated with the CoQ synthome.
The Human COQ9 Polypeptide Associates
with the Yeast Q-Biosynthetic Complex
To determine whether the human COQ9 polypeptide might
interact with yeast components of the CoQ synthome (He
et al., 2014), we expressed human COQ9 in the yeast strain
Coq6-CNAP (CNAP6). We chose Coq6-CNAP as the bait
protein because Coq9 is known to be important for the Coq6
hydroxylation step (Xie et al., 2012). A consecutive non-
denaturing tag containing a His10 tag and protein C epitope was
integrated at the C-terminus of yeast Coq6, resulting in Coq6-
CNAP (Allan et al., 2015). The CNAP6 strain has normal levels
of Coq6 and Q6 and co-precipitates other Coq polypeptides in
the CoQ synthome (Coq4, Coq5, Coq7, Coq8, and Coq9) (Allan
et al., 2015). Mitochondria purified from CNAP6:mcHCOQ9
were solubilized with digitonin and subjected to co-precipitation
over Ni-NTA resin. Fractions corresponding to flow through
(FT), washes (W1 and W2), eluates (E1 and E2), and beads
after elution were analyzed by SDS-PAGE and Western blot.
We found that unprocessed human COQ9 and yeast Coq9 co-
purified with Coq6-CNAP, (Figure 4). As a negative control, we
also blotted with an antibody against Atp2. As expected, Atp2
did not co-purify with Coq6-CNAP (Figure 4). The majority
of human COQ9 was detected in the flow through and wash
fractions, indicating the interaction between human COQ9 and
the Coq6-containing complex is weak or that only a small fraction
of the over-expressed human COQ9 interacted with the yeast
CoQ synthome (which is not over-expressed).
DISCUSSION
In this study, the yeast coq9 temperature-sensitive mutant,
∆coq9K:TS19, was rescued by the expression of human COQ9
containing the yeast Coq3 mitochondrial leader sequence.
Expression of human COQ9 increased the growth of the
∆coq9K:TS19 mutant on medium containing a non-fermentable
carbon source (Figure 1), and Q6 content (Figure 2). Such
rescue was observed at both permissive and non-permissive
temperatures. We also found that even though both multi-copy
Coq8 and human COQ9 rescued the yeast∆coq9K:TS19 mutant,
human COQ9 dramatically increased the level of 13C6-Q6 only
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FIGURE 3 | Expression of human COQ9 stabilizes yeast Coq polypeptides in the temperature-sensitive coq9 mutant at permissive temperature. W30319K harboring
the temperature-sensitive plasmid TS19 (19K:TS19) were transformed with multi-copy human COQ9 (19K:TS19+mcHCOQ9). Yeast strains W3031B (WT),
19K:TS19, and 19K:TS19+mcHCOQ9 were grown for 18.5 h at either 25 or 37◦C. Mitochondria were then purified from these yeast cultures. Mitochondria were
also isolated from the null control strains BY47411COQ9 (19), W3031COQ4 (14) (A), W3031COQ7 (17) (B), and W3031COQ6 (16) (C) after yeast were grown
overnight at 30◦C. Purified mitochondria (15 µg protein) were separated by SDS-PAGE and analyzed by Western blot. Immunoblots were performed with antibodies
against the designated polypeptides: Coq4, Coq6, Coq7, Coq9, human COQ9, and Atp2. M denotes the molecular weight marker.
FIGURE 4 | The human Coq9 polypeptide associates with yeast Coq6.
Mitochondria were isolated from CNAP6 and CNAP6:mcHCOQ9. Purified
mitochondria (13 mg) were solubilized and co-precipitation was then
performed on the solubilized mitochondria with Ni-NTA resin. Flow-through
(FT), wash (W1 and W2), eluate (E1 and E2), and beads from co-precipitation
were collected. 0.17% of the FT, 0.25% of W1, 0.25% of W2, 1% of E1, 0.5%
of E2, and 1.25% of Ni-NTA resin were analyzed by SDS-PAGE followed by
immunoblotting with antibodies against yeast Coq9, Coq6, human COQ9, and
Atp2. Purified mitochondria (15 µg) from CNAP6:mcHCOQ9 were included as
control.
when 13C6-4HB was the precursor (Figure 2C) but not when
13C6-pABA was the precursor (Figure 2A). In contrast, multi-
copy Coq8 increased the level of 13C6-Q6 when
13C6-pABA was
provided (Figure 2A). These findings suggest that human COQ9
increases Q6 production by promoting the conversion of 4HB to
Q6. Our findings are consistent with the observation that yeast
can utilize pABA to synthesize Q (Marbois et al., 2010), while
human cells are unable to utilize pABA (Xie et al., 2015). A recent
study proposed that Coq6, an FAD-dependent monooxygenase,
is responsible for the deamination reaction at the C4 position of
Q intermediates in yeast (Ozeir et al., 2015). Yeast Coq9 is also
required for the removal of nitrogen group of Q intermediates
(He et al., 2015), possibly by interacting with the C-terminal
region of Coq6, which is important for the C4-deamination
(Ozeir et al., 2015). Interestingly, humanCOQ6 promotes the C4-
deamination in yeast in the absence of yeast Coq9 (Ozeir et al.,
2015). It is possible that Coq9 is indispensable for the function
of Coq6 as a deaminase in yeast, but has an inhibitory effect on
the C4-deamination in humans. This could explain the inability
of human cells to use pABA as a Q precursor, but this hypothesis
will require further investigation.
Human COQ9 failed to rescue yeast coq9 null mutant, even
with the over-expression of yeast Coq8, which is known to
stabilize the CoQ-synthome (He et al., 2014; Figure 1). This
might be due to the fact that yeast Coq9 is required for the
function of yeast Coq6 and Coq7. Yeast coq6 and coq9 null
mutants over-expressing COQ8 both accumulate 4-AP when
pABA is provided as the ring precursor and yeast coq7 and coq9
null mutants over-expressing COQ8 both accumulate DMQ6
when 4-HB is provided (Xie et al., 2012). Yeast Coq6 and Coq7 do
not function well without yeast Coq9. The temperature sensitive
yeast Coq9-ts19 polypeptide may play a structural or regulatory
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role that enables human COQ9 to function in yeast. Interestingly,
the expression of humanCOQ9 stabilizes the steady state levels of
Coq4, Coq6, Coq7, and yeast Coq9 at permissive temperature. It
was shown that supplementation of Q6 to yeast mutants stabilizes
the CoQ-synthome and its Coq polypeptide subunits (He et al.,
2014), hence it is possible that human COQ9 stabilizes yeast
Coq proteins by increasing Q6 levels. Although we saw that
Q6 levels of 19K:TS19 were significantly increased by human
COQ9 at both permissive and non-permissive temperature
(Figure 2), human COQ9 stabilizes the steady state levels of
yeast Coq polypeptides only at the permissive temperature
(Figure 3). This observation may be due to the fact that our
LC-MS/MS assay is highly sensitive and small changes in lipid
levels are readily detected, while immunoblot assays may not
be sufficiently sensitive to reveal small changes in protein levels
affected by the expression of human COQ9 at non-permissive
temperature.
In order to investigate the mechanism of human COQ9
rescue of the yeast coq9 mutant, we determined whether human
COQ9 is associated with the CoQ-synthome. The structure
of human COQ9 was recently identified as a dimer (Lohman
et al., 2014). We speculated that human COQ9 might interact
with yeast Coq polypeptides. We performed co-precipitation of
CNAP-tagged yeast Coq6 and found that a small amount of
human COQ9, along with yeast Coq9, co-precipitates with Coq6-
CNAP (Figure 4). Therefore, human COQ9 interacts with the
yeast CoQ-synthome, reflecting a profound degree of functional
conservation. It is unusual that the unprocessed form of hCOQ9
is the sole form recovered together with yeast Coq6-CNAP.
The 39kDa form of hCOQ9 persists in isolated mitochondria
at the permissive temperature suggesting that mitochondrial
processing (i.e., removal of the N-terminal targeting peptide) of
the human protein is not as efficient as it is for the yeast protein
(assuming that the 39kDa band is the unprocessed form). Perhaps
this form may be better suited to interact with Coq6-CNAP, as
the 30kDa form of hCOQ9 may be truncated inappropriately or
otherwise modified in a way that prohibits this interaction. It
does seem apparent that the hCOQ9 will not necessarily interact
with the yeast proteins in the exact same way as the yeast Coq9
polypeptide.
We speculate that hCOQ9 may perform a similar enzymatic
or structural role as yeast Coq9, however, the presence of the
yeast tsCoq9 polypeptide is required to interact and stabilize the
other yeast Coq polypeptides. Thus, the yeast tsCoq9 polypeptide
may harbor mutations in regions important either for enzymatic
functions or protein-protein interactions, which render it less
efficient than wild-type Coq9. Expression of hCOQ9 alleviates
some of the deficiencies, but at this point we cannot distinguish
the exact mechanisms.
In conclusion, we found that human COQ9 interacts
with the CoQ-synthome and stabilizes the complex. We
speculate that human COQ9 stabilizes the complex by
increasing Q6 content derived from 4HB; as a result, it
rescues the growth of coq9-ts19 mutant at the non-permissive
temperature.
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